Core Insights - Oculis Holding AG announced the presentation of Phase 2 data for Privosegtor at the NANOS 52nd Annual Meeting, highlighting its commitment to addressing unmet medical needs in neuro-ophthalmology [1][2]. Company Overview - Oculis is a global biopharmaceutical company focused on innovations in ophthalmology and neuro-ophthalmology, with a late-stage clinical pipeline that includes three core product candidates: Privosegtor, OCS-01, and Licaminlimab [10]. - Privosegtor is a novel peptoid small-molecule candidate that has received Breakthrough Therapy designation from the FDA for optic neuritis (ON) and is entering registrational trials for ON and non-arteritic anterior ischemic optic neuropathy (NAION) [6][10]. Clinical Trial Results - The ACUITY Phase 2 trial results demonstrated significant improvements in low contrast visual acuity and neuroprotective effects in patients with optic neuritis, indicating Privosegtor's potential as the first neuroprotective therapy for this condition [4][6]. - The trial showed anatomical preservation of the retina and improvements in visual function after acute episodes of optic neuritis, with consistent results observed in animal models [6]. Event Participation - Oculis served as a Platinum Sponsor at the NANOS 2026 Congress, emphasizing its role in advancing scientific progress in neuro-ophthalmology [2][5]. - The presentation at NANOS represents a significant milestone for Oculis and the scientific community, showcasing groundbreaking data from the ACUITY trial [5]. Expert Involvement - Professor Martin Zinkernagel, a recognized expert in ophthalmology, presented the trial results, underscoring the importance of the findings in the context of neuro-ophthalmic science [5][7].